1. Межевитинова Е.А., Прилепская В.Н. Предменструальный синдром. Гинекология. 2002; приложение: 3–8.
2. Merikangas KR, Foeldenyi M, Angst J. The Zurich Study. XIX. Patterns of menstrual disturbances in the community:results of the Zurich Cohort Study. Eur Arch Pdychiatry ClinNeurosci 1993; 243: 23–32.
3. Stewart A. A rational approach to treating the premenstrual syndrome. Seal, Kent: National Association of Premenstrual Syndrome, 1989.
4. Wyatt K, Dimmock P, Jones P et al. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ 2001; 323: 1–8.
5. Van der Meer, Benedek-Jazmann LJ, Van Loenen AC. Efect of high-dose progesterone on the premenstrual syndrome; a double-blind crossover trial. J Psychosom Obstet Gynaecol 1983; 2: 220–2.
6. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. A double-blind trial of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome. JAMA 1995; 274: 51–7.
7. Dennerstein L, Spencer-Gardner C, Gotts G et al. Progesterone and the premenstrual syndrome: a double-blind crossover trial. BMJ 1985; 290: 1617–21.
8. Vanselow W, Dennerstein L, Greenwood KM, de Lignieres B. Effect of progesterone о and its 5 alpha and 5 beta metabolites on symptoms of premenstrual syndrome according to route of administration. J Psychosom Obstet Gynaecol 1996; 17: 29–38.
9. Maxson WS. The use of progesterone in the treatment of premenstrual syndrome. Clin Obstet Gynecol 1987; 30: 465–77.
10. West СР. Inhibition of ovulation with oral progestins – effectiveness in premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol 1990; 34: 19–28.
11. Dennerstein L, Morse C, Gotts G et al. Treatment of premenstrual syndrome. A double-blind trial or dydrogesterone. J Affect Disord 1986; 11: 199–205.
12. Williams JGC, Martin AJ, Hulkenberg-Tromp A. Premenstrual syndrome in four European countries. Part. A double-blind controlled study of dydrogesterone. Br J Sexual Med 1983; 10: 8–18.
13. Andersch B, Hahn L. Progesterone treatment of premenstrual tension – a double-blind study. J Psychosom Res 1985; 29: 489–93.
14. Maddocks S, Hahn P, Moller F, Reid RL. A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome. Am J Obstet Gynecol 1986; 154: 573–81.
15. Rapkin AJ, Chang LH, Reading AE. Premenstrual syndrome; a doubleOblind placebo-controlled study of treatment with progesterone vaginal suppositories. J Obstet Gynecol 1987; 7: 217–20.
16. Corney RH, Stanton R, Newell R. Comparison of progesterone, placebo and behavioural psychotherapy in the treatment of premenstrual syndrome. J Psychosom Obstet Gynaecol 1990; 11: 211–20.
17. Freeman EW, Rickels K, Sondheimer SJ, Polansky M. Ineffectiveness of progesterone suppository treatment for premenstrual syndrome. JAMA 1990; 264: 349–53.
18. Magill PJ. Investigation of the efficacy of progesterone pessaries in the relief of symptoms of premenstrual syndrome. Progesterone study Group. Br J Gen Pract 1995; 45: 589–93.
19. Watson NR, Studd JW, Savvas M et al. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet 1989; 2: 730–2.
20. Dhar V, Murphy BE. Double-blind randomized crossover trial of luteal phase estrogens (Premarin) in the premenstrual syndrome. Psychoneuroendocrinology 1990; 15: 489–93.
21. De Lignieres B, Vincens M, Mauvais-Jarvis P, Mas JL, Touboul PJ, Bousser MG. Prevention of menstrual migraine by percutaneous oestradiol. BMJ 1986; 293: 1540.
22. Kouri EM, Halbreich U, Hormonal treatments for premenstrual syndrome. Drugs today (Barc). 1998 Jul; 34 (7): 603–10.
23. Derzko CM. Role of danazol in relieving the premenstrual syndrome. J Reprod Med 1990 Jan; 35 (1 Suppl.): 97–102.
24. Hahn PM, van Vugt DA, Reid RL. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. Psychoneuroendocrinology. 1995; 20 (2): 193–209.
25. Halbreich U, Rojansky N, Palter S. Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes. Fertil Steril. 1991 Dec; 56 (6): 1066–9.
26. Watts JF, Butt WR, Logan ER. A clinical trial using danazol for the treatment of premenstrual tension. Br J Obstet Gynaecol 1987; 94: 30–4.
27. Sarno APJ, Miller EJJ, Lundblad EG. Premenstrual syndrome: beneficial effects of periodic, low-dose danazol. Obstet Gynecol 1987; 70: 33–6.
28. O'Brian PMS, Abukhalil IEH. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase only danazol. An J Obstet Gynecol 1999; 180: 18–23.
29. Sundstrom I, Nyberg S, Bixo M et al. Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen. Acta Obstet Gynecol Scand 1999 Nov; 78 (10): 891–9.
30. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonists in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol Bull 1997; 33 (2): 303–9.
31. Studd J, Leather AT. The need for add-back with gonadotrophin-releasing hormone agonist therapy. Br J Obstet Gynaecol 1996 Oct; 103 (Suppl. 14): 1–4.
32. Mortola JF. From GnRH to SSRIs ana Beyond: Weighing the Options for Drug Therapy in Premenstrual Syndrome. Medscape Womens health. 1997 Oct; 2 (10): 3.
33. Halbreich U. Treatment of premenstrual syndromes with progesterone antagonists (e.g.,RU-486): political and methodological issues. Psychiatry 1990 Nov; 53 (4): 407–9.
34. Chan AF, Mortola JF, Wood SH, Yen SS. Persistence of premenstrual syndrome during low-dose administration of the progesterone antagonist RU 486. Obstet Gynecol 1994 Dec; 84 (6): 10001–5.
35. Srbmidt PJ, Neiman LK, Grover GN et al. Lack of effect of induced mences on symptoms in women with premenstrual syndrome. N Engl J Med 1991 Apr 25; 324 (17): 1174–9.
36. Graham С A, Sherwin BB. Tne relationship between retrospective premenstrual syndrome reporting and present oral contraceptive use. J Psychosom Res 1987; 31: 45–53.
37. Backstrom T, Hanason-Malmstrom Y, Lindhe BA et al. Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations. Contraception 1992; 46: 253–68.
38. Abraham S, Luscombe G, Soo I. Oral contraception and cyclic changes in premenstrual and menstrual experiences. J Psychosom Obstet Gynaecol 2003 Sep; 24 (3): 185–9.
39. Bancroft J, Rennie D. The impact of oral contraceptives on the experience of perimenstrual mood, clumsiness, food craving and other symptoms. J Psychosom Res 1993; 37: 195–202.
40. Hallman J. The premenstrual syndrome – an equivalent of depression. Acta Psychiatr Scand 1986 Apr; 73 (4): 403–11.
41. Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 micro gram ethinylestradiol. Contraception 2004 Jun; 69 (6): 469–76.
42. Williams CL, Stancel GM. Estrogens and progestins. In Goodman and Gilman's Pharmacological Basis of Therapeutics. Ninth edition. Edited by JG Hardman, LE Limbird, PB Molinoff et al. New York, McGraw-Hill, 1996; 1411–37.
43. Huber J, Foidart JM, Wuttke W. Efficacy and tolerability of a monophasic oral contraceptive containing ethynilestradiol and drospirenone. Eur J Contracept reprod Health Care 2000; 5: 25–34.
44. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralcorticoid activity. Arzneimittelforschung 1985; 35: 459–71.
45. Muhn P, Fuhrmann U, Fritzemeier KH et al. Drospirenone: a novel progestogen with antimineralcorticoid and antiandrigenic activity. Ann N Y Acad Sci 1995; 761: 311–35.
46. Oelkers W, Helmerhorst FM, Wuttke W et al. Effect of an oral contraceptive containing drospirenone on the rennin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol 2000; 14: 204–13.
47. Oelkers W, Foidart JM, Dombrovicz et al. Effects of a new oral contraceptive containing an antimineralcorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endorinol Metab 1995; 80: 1816–21.
48. Losert W, Casals-Stenzel J, Buse M. Progestogens with antimineralcorticoid activity. Arzneimittelforschung 1985; 35: 459–71.
49. Foidart JM, Wuttke W, Bouw GM et al. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur J Contracept Reprod Health Care 2000; 5: 124–34.
50. Oelkers W, Foidart JM, Dombrovicz et al. Effects of a new oral contraceptive containing an antimineralcorticoid progestogen, drospirenone, on the rennin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endorinol Metab 1995; 80: 1816–21.
51. Fuhrmann U, Krattenmacher R, Slater EP et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996; 54: 243–51.
52. Mansour D Experiences with Yasmin: the acceptability of a novel oral contraceptive andits effect on well-being. Eur J Contracept reprod Health Care. 2002 Dec; 7 (Suppl. 3): 35–41.
53. Apter D, Borsos A, Baumgartner W et al. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
54. Wiklund I, Dimenas E, Wahl M. Factors of importance when evaluating quality of life in clinical trials. Control Clin Trials 1990; 11: 169–79.
55. Borenstein J, Yu HT, Wade S et al. Effect of an oral contraceptive containing ethinyl estradiol and drospirenone on premenstrual symptomatology and health-related quality of life. J Reprod Med 2003 Feb; 48 (2): 79–85.
56. Boschitch E, Skarabis H, Wuttke W et al. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being. The Eur J of Contracept and Reprod Health Care 2000; 5 (suppl. 3): 34–40.
57. Brown C, Ling F, Wan J. A new monophasic oral contraceptive containing drospirenone. Effect on premenstrual symptoms. J Reprod Med 2002 Jan; 47 (l): 14–22.
58. Freeman EW, Kroll R, Rapkin A et al. PMS/PMDD Research Group. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med 2001 Jul-Aug; 10 (6): 561–9.
59. Freeman EW. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder. Eur J Contracept Reprod Health Care 2002 Dec; 7 (Suppl): 27–34; discussion 42–3.
60. Grimes DA et al. Supression of menstruation with extended ОС regimens. The Contraception Report 2002; 13 (3): 8–11. 
61. Sulak P, Scow RD, Preece C et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000; 95: 261–6.
62. Loudon NB, Foxwell M, Potts DM et al. Acceptability of an oral contraceptive that reduces the frequency: The tri-cycle pill regimen. BMJ 1977; 2: 487–90.
63. Couthino EM, Segal SJ. Is menstruation Obsolete? New York: Oxford University Press, 1999.
64. Kaunitz AM. Menstruation: choosing whether...and when. Contraception 2000; 62: 277–84.
65. Nelson AL. Whoose pill is it, anyway? Fam Plann Perspect 2000; 32: 89–90.
66. Clarke AK, Miller SJ. The debate regarding continuous use of oral contraceptives. Ann Pharmacother 2001; 35: 1480–4.
67. Schwartz JL, Creinin MD, Pymar HC. The trimonthly combination oral contraceptive regimen: Is it cost effective? Contraception 1999; 60: 263–7.
68. Sulak PJ, Kuehl TJ, Ortiz MJ, Shul BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol 2002; 186,6: 1142–49.
69. Schilling LH, Bolding ОТ, Chenault CB et al. Evaluation of the clinical performance of three triphasic oral contraceptives: A mufti-center, randomized comparative trial. Am J Obstet Gynecol 1989; 160: 1264–8.
70. Rosenberg MJ, Meyers A, Roy V. Efficacy, cycle control, and side effects of low and lower dose oral contraceptives: A randomized trial of 20 micrograms and 35 micrograms estrogen preparations. Contraception 1999; 60: 321–9.
71. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol 2001; 98 (5): 771–8.
72. Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception 2003; 67: 9–13.
73. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 2003; 68: 89–96.
74. Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs 2004; 64 (21): 2447–62.
75. Cachrimanidou A-C, Hellberg D, Nilsson S et al. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 1993; 48: 205–16.
76. Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management J Psychiatry Neurosci 2000.
77. Sulak PJ, Cressman BE, Waldrop E et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997; 89: 179–83.
78. Loudon NB, Foxwell M, Potts DM et al. Acceptability of an oral contraceptive that reduces the frequency of menstruation: the tri-cycle pill regimen. BMJ 1977; 2: 487–90.
79. Sillem M, Schneidereit R, Heithecker R, et al. Use of an oral contraceptive containing drospirenone in an extended regimen. Eur J Contracept Reprod Health Care 2003; 8: 162–9.

М.А.Тарасова, Т.М. Лекарева

ГУ НИИ акушерства и гинекологии им. Д.О.Отта РАМН, Санкт-Петербург